H.C. Andersen Bio Pharma ApS: Financial statements 2023
CVR: 38683462
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
H.C. Andersen Bio Pharma ApS (CVR 38683462) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 0 and a net result of DKK -1,599 compared with DKK -1,357 the year before. Equity in the 2023 report amounted to DKK -290,628.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,599
- Equity
- DKK -290,628
- Total Assets
- DKK 19,245
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 | 0 | -2 t. | -291 t. | - |
| 2022 | 0 | 0 | -1 t. | -289 t. | - |
| 2021 | 0 | -5 t. | -7 t. | -288 t. | - |
| 2020 | 2 t. | -111 t. | -112 t. | -281 t. | - |
| 2019 | - | -11 t. | -12 t. | -169 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
H.C. Andersen Bio Pharma ApS has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -1,357.
About H.C. Andersen Bio Pharma ApS
H.C. Andersen Bio Pharma ApS was a Danish company of the type Anpartsselskab based in København S, founded in 2017. The company has been dissolved on 24 July 2026. The company was registered under the industry Detailhandel med andre nye varer. The company was previously named H. C. Andersen Emeren Group ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,673 compared with DKK -20,418 the year before. Equity in the 2025 report amounted to DKK -312,718.